VCYT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Veracyte Inc (VCYT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite a minor pre-market dip, the company's strong financial performance, positive growth trends, and bullish analyst sentiment make it a compelling investment opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 76.08, and moving averages are converging, suggesting no immediate overbought or oversold conditions. Key support is at 34.548, and resistance is at 38.918, with the current pre-market price near resistance levels.
Strong Q4 2025 financial performance with revenue up 18.55% YoY and net income up 704.79% YoY.
Testing volumes for Decipher and Afirma grew by 21% and 12%, respectively.
Adjusted EBITDA margin exceeded targets at 27%.
Analyst price target raised to $50 with a Buy rating.
Revenue guidance for 2026 suggests continued growth of 10%-13%.
Pre-market price is down by 1.94%, reflecting minor short-term bearish sentiment.
Stock trend analysis predicts a potential decline of -1.78% in the next week and -2.37% in the next month, indicating short-term downside risk.
Veracyte's Q4 2025 financials show impressive growth: revenue increased by 18.55% YoY to $140.6M, net income surged by 704.79% YoY to $41.1M, and EPS rose by 750% YoY to $0.51. Gross margin improved to 72.07%, highlighting operational efficiency.
Guggenheim raised the price target to $50 from $45 and maintained a Buy rating, reflecting confidence in the company's growth prospects.
